The maker of technologies for treating spinal cord injuries InVivo Therapeutics Holdings Corp. announced the resignation of CEO and Chairman Francis M. Reynolds, effective Aug. 22. Michael J. Astrue, the nonexecutive chairman of the board at biopharmaceutical company Vivus Inc.,will serve as interim CEO while the board of directors conducts a search for a permanent CEO. Astrue has served in a number of government positions, most recently as commissioner of the Social Security Administration from 2007 to 2013. Also, Sean Moran, the company’s director of finance, will serve as acting chief financial officer, effective Aug. 22.
Last December, InVivo Therapeutics filed a request with FDA for a humanitarian use exemption for its biopolymer scaffolding device to treat acute spinal cord injuries. (See Also see "News...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?